Licensing status

Publication and contact information

Autoimmune disease

Inflammatory bowel disease (IBD); psoriasis

Tyrosine kinase 2 (TYK2)

In vitro and rodent studies suggest selectively inhibiting TYK2 could help treat IBD and psoriasis. In in vitro biochemical and cellular assays, an optimized aminopyridine benzamide derivative showed potent inhibition of TYK2 activity and was selective for TYK2 over off-target Janus kinases. In mice, oral treatment with the lead compound inhibited the IL-12 signaling pathway, which is associated with IBD and psoriasis. Next steps could include evaluating the TYK2 inhibitor in preclinical models for IBD and psoriasis.

SciBX 6(24); doi:10.1038/scibx.2013.592
Published online June 20, 2013

Patent and licensing status undisclosed

Liang, J. et al. J. Med. Chem.; published online May 14, 2013;
Contact: Jun Liang, Genentech Inc., South San Francisco, Calif.